Drug Profile
Research programme: antibacterials - Peplin
Latest Information Update: 13 Nov 2009
Price :
$50
*
At a glance
- Originator Neosil
- Developer Peplin
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Acne
Most Recent Events
- 12 Nov 2009 Peplin has been acquired by LEO Pharma
- 30 Sep 2009 Suspended - Preclinical for Acne in USA (unspecified route)
- 29 Oct 2008 Preclinical trials in Acne in USA (unspecified route)